ClinicalTrials.gg

Program

RO7836748

A development code.

Its studies are led by Hoffmann-La Roche.

Furthest: phase 1, since Oct 23, 20261 company-led study, 1 open or runningNext primary completion: Mar 30, 2032 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hoffmann-La Roche11 open or runningphase 1since Oct 23, 2026Oct 23, 2026Mar 30, 2032phase 1 · NCT07905924

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 23, 2026First study: phase 1 study in Solid TumorsFirst studyNCT07905924 · 540 planned

Ahead

  1. Mar 30, 2032Primary completion: phase 1 study in Solid TumorsNCT07905924

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07905924Solid Tumors1Not yet recruitingMar 30, 2032540

How it is read

Names in the registry

  • “RO7836748”, 1 entry

Codes read as this program: RO7836748.

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.